The caveat is the need for high doses required for longer periods, leaving the patient susceptible to life-threatening opportunistic infections such as tuberculosis in RA patients treated with TNF-α antibodies and long-term risk of malignancy [25]. Here, TNF is linked to rheumatoid arthritis.